Author: Wang, Qiang; Zhao, Ying; Chen, Xiaojia; Hong, An
Title: Virtual screening of approved clinic drugs with main protease (3CL(pro)) reveals potential inhibitory effects on SARS-CoV-2 Cord-id: wz645vg4 Document date: 2020_9_10
ID: wz645vg4
Snippet: 3CL(pro) is the main protease of the novel coronavirus (SARS-CoV-2) responsible for their intracellular duplication. Based on virtual screening technology and molecular dynamics simulation, we found 23 approved clinical drugs such as Viomycin, Capastat, Carfilzomib and Saquinavir, which showed high affinity with the 3CL(pro) active sites. These findings showed that there were potential drugs that inhibit SARS-Cov-2's 3CL(pro) in the current clinical drug library, and these drugs can be further t
Document: 3CL(pro) is the main protease of the novel coronavirus (SARS-CoV-2) responsible for their intracellular duplication. Based on virtual screening technology and molecular dynamics simulation, we found 23 approved clinical drugs such as Viomycin, Capastat, Carfilzomib and Saquinavir, which showed high affinity with the 3CL(pro) active sites. These findings showed that there were potential drugs that inhibit SARS-Cov-2's 3CL(pro) in the current clinical drug library, and these drugs can be further tested or chemically modified for the treatment of COVID-19. Communicated by Ramaswamy H. Sarma
Search related documents:
Co phrase search for related documents- active site and lopinavir indinavir: 1, 2
- active site and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- active site and lopinavir ritonavir currently clinical trial: 1
- active site and lopinavir saquinavir: 1, 2
- adjuvant treatment and lopinavir ritonavir: 1
Co phrase search for related documents, hyperlinks ordered by date